TY - JOUR
T1 - Classification of Local Recurrence After Nipple-Sparing Mastectomy Based on Location
T2 - The Features of Nipple–Areolar Recurrence Differ from Those of Other Local Recurrences
AU - Yamaguchi, Ayu
AU - Ishitobi, Makoto
AU - Nagura, Naomi
AU - Shimo, Ayaka
AU - Seki, Hirohito
AU - Ogiya, Akiko
AU - Sakurai, Teruhisa
AU - Seto, Yukiko
AU - Oshiro, Chiya
AU - Sasada, Shinsuke
AU - Kato, Michiko
AU - Kawate, Takahiko
AU - Kondo, Naoto
AU - Narui, Kazutaka
AU - Nakagawa, Tsuyoshi
AU - Nogi, Hiroko
AU - Yamauchi, Chikako
AU - Tsugawa, Koichiro
AU - Kajiura, Yuka
AU - Shien, Tadahiko
N1 - Funding Information:
This study was supported in part by grants-in-aid for scientific research from the Japan Oncoplastic Breast Surgery Society. The authors thank Angela Morben, DVM, ELS, from Edanz ( https://jp.edanz.com/ac ) for editing a draft of this manuscript.
Publisher Copyright:
© 2022, Society of Surgical Oncology.
PY - 2022
Y1 - 2022
N2 - Background: Little information is available about the clinical and pathologic characteristics of local recurrence (LR) after nipple-sparing mastectomy according to the locations of LR. Methods: This study classified 99 patients into the following two groups according to the location of LR after nipple-sparing mastectomy: nipple–areolar recurrence (NAR) group and other locations of LR (oLR) group. The study evaluated whether the location of LR was associated with disease-free survival (DFS) after LR resection. Results: For about half of the patients (44.4 %) with NAR, the primary cancer was estrogen receptor (ER)-negative and human epidermal growth factor receptor 2 (HER2)-positive. Conversely, in most of the patients with oLR (79.2 %), the primary cancer was ER-positive and HER2-negative. Among the LR tumors, the frequency of noninvasive carcinoma in the NAR tumors was significantly higher than in the oLR tumors (51.9 % vs 4.2 %, respectively). During a median follow-up period of 46 months, the location of LR was not associated with DFS after LR. In the NAR group, the presence or absence of LR tumor invasiveness was the only factor associated with DFS. In the oLR group, age at primary surgery was the only factor associated with DFS. Conclusion: This multi-institutional retrospective study demonstrated that the features of NAR, such as the characteristics of the primary and recurrent tumors and the prognostic factors after LR resection, were quite different from those of oLR.
AB - Background: Little information is available about the clinical and pathologic characteristics of local recurrence (LR) after nipple-sparing mastectomy according to the locations of LR. Methods: This study classified 99 patients into the following two groups according to the location of LR after nipple-sparing mastectomy: nipple–areolar recurrence (NAR) group and other locations of LR (oLR) group. The study evaluated whether the location of LR was associated with disease-free survival (DFS) after LR resection. Results: For about half of the patients (44.4 %) with NAR, the primary cancer was estrogen receptor (ER)-negative and human epidermal growth factor receptor 2 (HER2)-positive. Conversely, in most of the patients with oLR (79.2 %), the primary cancer was ER-positive and HER2-negative. Among the LR tumors, the frequency of noninvasive carcinoma in the NAR tumors was significantly higher than in the oLR tumors (51.9 % vs 4.2 %, respectively). During a median follow-up period of 46 months, the location of LR was not associated with DFS after LR. In the NAR group, the presence or absence of LR tumor invasiveness was the only factor associated with DFS. In the oLR group, age at primary surgery was the only factor associated with DFS. Conclusion: This multi-institutional retrospective study demonstrated that the features of NAR, such as the characteristics of the primary and recurrent tumors and the prognostic factors after LR resection, were quite different from those of oLR.
UR - http://www.scopus.com/inward/record.url?scp=85141666051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141666051&partnerID=8YFLogxK
U2 - 10.1245/s10434-022-12760-1
DO - 10.1245/s10434-022-12760-1
M3 - Article
C2 - 36371582
AN - SCOPUS:85141666051
SN - 1068-9265
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
ER -